| Autor: |
Hiromitsu Kumada, Masahiro Kobayashi, Yasuji Arase, Mariko Kobayashi, Satoshi Saito, Keiji Aoki, Tetsuya Hosaka, Yoshiyuki Suzuki, Yoshiyuki Nakayasu, Sachiyo Watahiki, Kenji Ikeda, Norio Akuta, Fumitaka Suzuki, Hidetaka Tsuda, Rie Mineta, Yuya Seko, Ichimaro Yamada, Hitomi Sezaki, Yusuke Kawamura |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Hepatology Research. 43:691-701 |
| ISSN: |
1386-6346 |
| DOI: |
10.1111/hepr.12009 |
| Popis: |
Aim The aims of this study are to assess the antiviral effects, safety and telaprevir (TVR) pharmacokinetics in two cohorts given TVR every 8 h (q8h) at doses of 500 mg and 750 mg with peginterferon-α-2b and ribavirin in chronic hepatitis C patients. Methods Twenty chronic hepatitis C (HCV) patients with genotype 1b in high viral loads were randomly assigned to two TVR-based regimens of 750 mg q8h (group A) and 500 mg q8h (group B) in combination with peginterferon-α-2b and ribavirin for 12 weeks. Results Although the difference was not statistically significant other than trough concentration (Ctrough) at week 4, the parameters of maximum concentration (Cmax), the area under the concentration time curve (AUC0–∞) and Ctrough tended to be higher in group A than those in group B. The antiviral effects were similar in the two groups (sustained virological response rates [SVR], 40% in group A, 50% in group B). The discontinuation rates by anemia were 30% in group A and 20% in group B. Serum creatinine concentrations were lower in group B than those in group A. Conclusion Although the exposure to TVR tended to be lower in 500 mg q8h than that in 750 mg q8h, the SVR rates in both groups were similar. The result suggests that the 500 mg q8h dose may be one option for treatment. In addition, the present findings indicate that the development of adverse events which increase with a TVR-based regimen, specifically anemia and creatinine, could be avoided by dose adjustment of TVR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text